---
figid: PMC6317949__CAS-110-52-g006
figtitle: The regulation of major histocompatibility complex class I (MHC‐I) expression
  in non–small cell lung cancer cells by epidermal growth factor receptor (EGFR)‐MEK‐extracellular
  signal‐regulated kinase (ERK) signaling
organisms:
- Homo sapiens
- Bos taurus
- Armoracia rusticana
- NA
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC6317949
filename: CAS-110-52-g006.jpg
figlink: /pmc/articles/PMC6317949/figure/cas13860-fig-0006/
number: F6
caption: Model for the regulation of major histocompatibility complex class I (MHC‐I)
  expression in non–small cell lung cancer cells by epidermal growth factor receptor
  (EGFR)‐MEK‐extracellular signal‐regulated kinase (ERK) signaling. Mutational activation
  of EGFR leads to down‐regulation of MHC‐I expression through the MEK‐ERK signaling
  pathway. EGFR‐tyrosine kinase inhibitors and the MEK inhibitor trametinib increase
  MHC‐I expression via inhibition of ERK activation. The increase in MHC‐I expression
  facilitates recognition of the cancer cells by intratumoral T cells and thereby
  promotes an antitumor immune response
papertitle: Mutational activation of the epidermal growth factor receptor down‐regulates
  major histocompatibility complex class I expression via the extracellular signal‐regulated
  kinase in non–small cell lung cancer.
reftext: Satomi Watanabe, et al. Cancer Sci. 2019 Jan;110(1):52-60.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9610786
figid_alias: PMC6317949__F6
figtype: Figure
redirect_from: /figures/PMC6317949__F6
ndex: a2b10659-dea2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6317949__CAS-110-52-g006.html
  '@type': Dataset
  description: Model for the regulation of major histocompatibility complex class
    I (MHC‐I) expression in non–small cell lung cancer cells by epidermal growth factor
    receptor (EGFR)‐MEK‐extracellular signal‐regulated kinase (ERK) signaling. Mutational
    activation of EGFR leads to down‐regulation of MHC‐I expression through the MEK‐ERK
    signaling pathway. EGFR‐tyrosine kinase inhibitors and the MEK inhibitor trametinib
    increase MHC‐I expression via inhibition of ERK activation. The increase in MHC‐I
    expression facilitates recognition of the cancer cells by intratumoral T cells
    and thereby promotes an antitumor immune response
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - EGFR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - Erk7
  - rl
  - Akt
  - Egfr
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Mtk
  - Trametinib
---
